724788-70-9

Basic information

• Product Name: 8-BROMO-7-FLUORO-2-METHOXY-1,5-NAPHTHYRIDINE
• Synonyms: 8-BROMO-7-FLUORO-2-METHOXY-1,5-NAPHTHYRIDINE;1,5-Naphthyridine,8-broMo-7-fluoro-2-Methoxy-;4-BroMo-3-fluoro-6-Methoxy-[1,5]naphthyridine
• CAS NO: 724788-70-9
• Molecular Formula: C₉H₆BrFN₂O
• Molecular Weight: 257.0591432
• Mol File: 724788-70-9.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 324.699°C at 760 mmHg
• Flash Point: 150.173°C
• Appearance: /
• Density: 1.665g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 8-BROMO-7-FLUORO-2-METHOXY-1,5-NAPHTHYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BROMO-7-FLUORO-2-METHOXY-1,5-NAPHTHYRIDINE(724788-70-9)
• EPA Substance Registry System: 8-BROMO-7-FLUORO-2-METHOXY-1,5-NAPHTHYRIDINE(724788-70-9)

Safety Data

• Hazardous Substances Data: 724788-70-9(Hazardous Substances Data)

Usage

General Description

8-Bromo-7-fluoro-2-methoxy-1,5-naphthyridine is a chemical compound with a molecular formula of C12H7BrFN2O. It is a naphthyridine derivative that contains bromine, fluorine, and methoxy functional groups. 8-BROMO-7-FLUORO-2-METHOXY-1,5-NAPHTHYRIDINE is used in pharmaceutical research and development, particularly in the synthesis of potential drug candidates. Its structure and properties make it a valuable building block for the design and synthesis of new drug molecules with potential therapeutic applications. Its unique chemical structure and reactivity make it a useful tool in drug discovery and development efforts.

InChI:InChI=1/C9H6BrFN2O/c1-14-7-3-2-6-9(13-7)8(10)5(11)4-12-6/h2-4H,1H3

Upstream product

• 38533-61-8 2-chloro-6-methoxy-3-nitropyridine 
• 724788-68-5 C₉H₆BrN₄O⁽¹⁺⁾ 
• 53241-92-2 4-Hydroxy-6-methoxy-[1,5]naphthyridine-3-carboxylic Acid Ethyl Ester 
• 53241-90-0 diethyl {[(6-methoxypyridin-3-yl)amino]methylidene}propanedioate 
• 23443-25-6 6-methoxy-1,5-naphthyridin-4-ol 
• 1075259-77-6 3-fluoro-6-methoxy-1,5-naphthyridin-4-ol 
• 724788-63-0 ethyl 6-methoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylate 
• 1417551-48-4 t-butyl 4-bromo-6-methoxy-1,5-naphthyridine-3-yl-carbamate 
• 724788-66-3 4-bromo-6-(methyloxy)-1,5-naphthyridin-3-amine 
• 724788-65-2 4-bromo-6-methoxy-1,5-naphthyridine-3-carboxylic acid 
• 724788-64-1 ethyl 4-bromo-6-methoxy-1,5-naphthyridine-3-carboxylate 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 1075259-75-4 2-fluoro-1-(6-methoxy-3-nitropyridin-2-yl)ethanone 
• 1075259-74-3 2-(1-ethoxyethylene)-6-methoxy-3-nitropyridine 

Downstream Products

• 881658-51-1 (E)-7-fluoro-2-methoxy-8-styryl-1,5-naphthyridine 
• 1616409-89-2 t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate 
• 1616409-88-1 t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate 
• 1415415-01-8 7-fluoro-2-methoxy-8-methyl-1,5-naphthyridine 
• 1207621-43-9 (3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-acetic acid ethyl ester 
• 1073495-66-5 C₁₈H₁₅FN₂O₅S 
• 943026-50-4 C₁₈H₁₅FN₂O₅S 
• 1173896-46-2 1-(2-(4-((3,4-dichlorobenzyl)amino)piperidin-1-yl)ethyl)-7-methoxy-1,5-naphthyridin-2(1H)-one 
• 959615-59-9 7-methoxy-1,5-naphthyridin-2(1H)-one 

Relevant articles and documents

1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition

The development of new therapies to treat methicillin-resistant Staphylococcus aureus (MRSA) is needed to counteract the significant threat that MRSA presents to human health. Novel inhibitors of DNA gyrase and topoisomerase IV (TopoIV) constitute one highly promising approach, but continued optimization is required to realize the full potential of this class of antibiotics. Herein, we report further studies on a series of dioxane-linked derivatives, demonstrating improved antistaphylococcal activity and reduced hERG inhibition. A subseries of analogues also possesses enhanced inhibition of the secondary target, TopoIV.

TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF

Disclosed are Type II Topoisomerase Inhibitors, analogs thereof, pharmaceutical compositions thereof, and methods of making and using these compounds and compositions. Methods of using the disclosed compounds to treat infections, such as MRSA, MDR P. aeruginosa, and other pathogens are also described.

Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents

Bacterial resistance is eroding the clinical utility of existing antibiotics necessitating the discovery of new agents. Bacterial type II topoisomerase is a clinically validated, highly effective, and proven drug target. This target is amenable to inhibit